Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1

Next Previous
Trial Profile

Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 11 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Neurofibroma
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 06 Jul 2016 Status changed from active, no longer recruiting to completed.
  • 13 Aug 2015 The recruitment status of this study is unknown because the information has not been verified recently (Verified on March 2013 ). So kept previous status as active not recruiting as per ClinicalTrials.gov record.
  • 11 Jan 2013 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top